Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent with a good patient tolerability profile would be a useful alternative for those patients for whom the main purpose of treatment is palliation. The novel nucleoside analog gemcitabine has proven single-agent activity in patients with NSCLC, with consistent response rates of 20% and above. This report reviews two randomized phase II studies of single-agent gemcitabine versus cisplatin/etoposide in patients with advanced NSCLC.